Neutropenia, agranulocytosis and dipyrone

Dipyrone and agranulocytosis: what is the risk?

THE LANCET • Vol 361 • March 15, 2003 • http://image.thelancet.com/extras/02cor12094web.pdf trigger immune reactions in patients not previously exposed to the drug and to manifest sepsis or pneumonia due to dipyrone-induced agranulocytosis. Therefore, short-term studies miss the life-threatening or fatal risks of the drug. It is not lack of efficacy, but an excessive rate of serious adverse rea...

Clozapine, agranulocytosis, and benign ethnic neutropenia.

C lozapine is an atypical antipsychotic that is effective in treatment resistant schizophrenia. The National Institute for Health and Clinical Excellence (NICE) guidelines for schizophrenia specify that ‘‘in individuals with evidence of treatment resistant schizophrenia, clozapine should be introduced at the earliest opportunity’’. A severe adverse effect of clozapine that limits its more wides...

Severe Mucor necrotizing fasciitis associated to dipyrone-induced agranulocytosis.

Pharmacovigilance and Pharmacoepidemiology Clinical Particularities of Drug-Induced Agranulocytosis or Severe Neutropenia in Elderly Patients

Agranulocytosis is a life-threatening disorder in any age and also in the elderly subjects who are receiving on the average a larger number of drugs than younger subjects. This disorder frequently occurs as an adverse reaction to drugs, particularly to antibiotics, antiplatelet agents, antithyroid drugs, neuroleptics or anti-epileptic agents and nonsteroidal anti-inflammatory agents. Although p...

Agranulocytosis